Literature DB >> 26150126

Gout: Why compare the effectiveness of suboptimal gout management?

Nicola Dalbeth1, Lisa K Stamp2.   

Abstract

Comparative effectiveness research could help inform the choice of agent for urate-lowering therapy, the central component of successful gout management. However, if such studies reflect current clinical practice, are they comparing poor management with inadequate management?

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26150126     DOI： 10.1038/nrrheum.2015.94

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  8 in total

1.  Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.

Authors:  Lisa K Stamp; John L O'Donnell; Mei Zhang; Jill James; Christopher Frampton; Murray L Barclay; Peter T Chapman
Journal:  Arthritis Rheum       Date:  2011-02

2.  2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Authors:  Dinesh Khanna; John D Fitzgerald; Puja P Khanna; Sangmee Bae; Manjit K Singh; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

3.  Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Authors:  Michael A Becker; H Ralph Schumacher; Robert L Wortmann; Patricia A MacDonald; Denise Eustace; William A Palo; Janet Streit; Nancy Joseph-Ridge
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

4.  Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study.

Authors:  Frances Rees; Wendy Jenkins; M Doherty
Journal:  Ann Rheum Dis       Date:  2012-06-07       Impact factor: 19.103

5.  The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.

Authors:  Michael A Becker; H Ralph Schumacher; Luis R Espinoza; Alvin F Wells; Patricia MacDonald; Eric Lloyd; Christopher Lademacher
Journal:  Arthritis Res Ther       Date:  2010-04-06       Impact factor: 5.156

6.  Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

Authors:  H Ralph Schumacher; Michael A Becker; Robert L Wortmann; Patricia A Macdonald; Barbara Hunt; Janet Streit; Christopher Lademacher; Nancy Joseph-Ridge
Journal:  Arthritis Rheum       Date:  2008-11-15

7.  Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.

Authors:  Jasvinder A Singh; Kasem S Akhras; Aki Shiozawa
Journal:  Arthritis Res Ther       Date:  2015-05-12       Impact factor: 5.156

8.  Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study.

Authors:  Robert D Goldfien; Michele S Ng; Goldie Yip; Alice Hwe; Alice Jacobson; Alice Pressman; Andrew L Avins
Journal:  BMJ Open       Date:  2014-01-10       Impact factor: 2.692
  8 in total
  2 in total

1.  Racial disparities in the risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States.

Authors:  Na Lu; Sharan K Rai; Robert Terkeltaub; Seoyoung C Kim; Mariano E Menendez; Hyon K Choi
Journal:  Semin Arthritis Rheum       Date:  2016-03-31       Impact factor: 5.532

2.  Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.

Authors:  Hsin-Wen Chang; Ya-Wen Lin; Ming-Hung Lin; Yu-Ching Lan; Ruey-Yun Wang
Journal:  PLoS One       Date:  2019-01-07       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.